Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Regeneron in $400M senior note deal

This article was originally published in Scrip

Executive Summary

Regeneron Pharmaceuticals said it has priced a $400 million offering involving the sale of $1.875% senior convertible notes due 1 October 2016. A At the close, the company expects net proceeds of about $391.3 million after expenses. The notes have an initial conversion price of $84.02 per share, which is about a 30% premium to Regeneron's close of $64.63 on 17 October, the day before the deal was announced.

Advertisement

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC014896

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel